ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 131. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-97. 132. Royal College of Obstetricians and Gynaecologists. Cardiac Disease and Pregnancy. Good Practice Não. 13. London: RCOG; 2011. 133. Anim-Somuah M, Smyth RM, Jones L. Epidural versusnon-epidural or Não analgesia in labour. Cochrane Database Syst Rev. 2011 Dec;(12):CD000331. 134. Likis FE, Andrews JC, CollinsMR, Lewis RM, Seroogy JJ, Starr SA, et al. Nitrous oxide for the management oflabor pain: a systematic review. AnesthAnalg. 2014;118(1):153-67. 135. Langesæter E, Dragsund M, Rosseland LA. Regional anaesthesia for a Caesarean section in women with cardiac disease: a prospective study. Acta Anaesthesiol Scand. 2010;54(1):46-54. 136. Lewis NL, DobDP, Yentis SM. UK registry of high-risk obstetric anaesthesia: arrhythmias, cardiomyopathy, aortic stenosis, transposition of the great arteries and Marfan’s syndrome. Int J Obstet Anesth. 2003;12(1):28-34. 137. E Isogai T, Matsui H, TanakaH, Kohyama A, Fushimi K YasunagaH. Clinical features and peripartum outcomes in pregnant women with cardiac disease: a nationwide retrospective cohort study in Japan. Heart Vessels. 2018;33(8):918-30. 138. Hamlyn EL, Douglass CA, Plaat F, Crowhurst JA, Stocks GM. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. Int J Obstet Anesth. 2005;14(4):355-61. 139. Cohen KM, Minehart RD, Leffert LR. Anesthetic Treatment of Cardiac Disease During Pregnancy. Curr Treat Options Cardiovasc Med. 2018;20(8):66. 140. Langesæter E, Gibbs M, Dyer RA. The role of cardiac output monitoring in obstetric anesthesia. Curr Opin Anesthesiol. 2015;28(3):247-53. 141. American Society of Anesthesiologists Task Force onObstetric Anesthesia. Practice guidelines for obstetric anestesia. An updated report by the American Society of Anesthesiologists Task Force onObstetric Anesthesia. Anesthesiology. 2007;106(4):843-63. 142. D’Angelo R, Smiley RM, Riley ET, Segal S. Serious complications related to obstetric anesthesia: the serious complication repository project of the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2014;120(6):1505-12. 143. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology. 2004;101(4):950-9. 144. Leffert L, Butwick A, Carvalho B, Arendt K, Bates SM, Friedman A, et al. The Society for Obstetric Anestesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. Anesth Analg. 2018;126 (3):928-44. 145. AvilaWS, Rossi EG, Ramires JA, Grinberg M, BortolottoMR, ZugaibM, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol. 2003;26(3):135-42. 146. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H,et al. Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease. Circulation. 2018;137(8):806-16. 147. Thorne S, MacGrecor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart. 2006;92(10):1520-5. 148. Sliwa K, Johnson MR, Zilla P, Roos-Hesselink JW. Management of valvular disease in pregnancy: a global perspective. Eur Heart J. 2015;36(18):1078-89. 149. Tarasoutchi F, Montera MW, Grinberg M, Barbosa MR, Piñeiro DJ, Sánchez CRM, et al. Brazilian Guidelines for Valve Disease - SBC 2011 / I Guideline Inter-American Valve Disease - 2011 SIAC. Arq Bras Cardiol. 2011;97(5 Suppl 1):1-67. 150. Tarasoutchi F, Montera MW, Ramos AI, Sampaio RO, Rosa VEE, Accorsi TAD,etalAtualizaçãodasDiretrizesBrasileirasdeValvopatias:Abordagem das Lesões Anatomicamente Importantes. Arq Bras Cardiol. 2017;109(6 Suppl 2):1-34. 151. Nishimura RA, OttoCM, BonowRO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACCGuideline for theManagement of PatientsWith Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159-95. 152. AvilaWS,Rossi,EG,GrinbergM,Ramires JA. Influenceofpregnancyaafter bioprosthetic valve replacement in young women: A prospective five-year study. J Heart Valve Dis. 2002;11(6):864-9. 153. Avila WS, Lobo CG Abreu SB, Bortolotto MR, Testa CB, Tarasoutchi F,et al. Pregnancy and heart valve prostheses: maternal and fetal outcomes. Comparative study. Eur Heart J. 2018;39(Suppl1):1126. 154. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(6):797-806. 155. Xu Z, Fan J, Luo X, ZhangWB, Ma J, Lin YB, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: A systematic review and meta-analysis. Can J Cardiol. 2016;32(10):1248.e1-1248.e9 156. Vause S, Clarke B, Tower CL, Hay C, Knight M. Pregnancy outcomes in women with mechanical prosthetic heart valves: A prospective descriptive population based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system. BJOG. 2017;124(9):1411-9. 157. Abildgaard U, Sandset PM, Hammerstrom J, Gjestvang FT, Tveit A. Management of pregnant womenwithmechanical heart valve prosthesis: Thromboprophylaxis with low molecular weight heparin. Thromb Res. 2009;124(3):262-7. 158. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa with therapeutic enoxaparian during pregnancy. J Perinatol. 2010;30(4):253-7. 159. Goland S, Schwartzenberg S, Fan J, Kozak N, Khatri N, Elkayam U. Monitoringof anti-Xa in pregnant patients with mechanical prosthetic valves receiving lowmolecular-weight heparin: Peak or trough levels? J Cardiovasc Pharmacol Ther. 2014;19(5):451-6. 160. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. Anticoagulation for pregnant women with mechanical heart valves: A systematic review and meta-analysis. Eur Heart J. 2017;38(19):1509-16. 161. SousaAR,BarreiraR,SantosE.Low-dosewarfarinmaternalanticoagulation and fetal warfarin syndrome. BMJ Case Rep. 2018 Apr 7;2018. pii: bcr- 2017-223159. 162. Basu S, Aggarwal P, Kakani N, Kumar A. Low-dosematernal warfarin intake resulting in fetal warfarin syndrome: In search for a safe anticoagulant regimen during pregnancy. Birth Defects Res A Clin Mol Teratol. 2016;106(2):142-7. 163. Van Driel D, Wesseling J, Sauer PJ, Touwen BC, van der Veer E, Heymans HS. Teratogen update: Fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66(3):127-40. 164. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, KaouacheM. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749-56. 165. Balint OH, Siu SC, Mason J, Grewal J, Wald R, Oechslin EN, et al. Cardiac outcomes after pregnancy in womenith congenital heart disease. Heart. 2010;96(20):1656-61. 934